ESC Professional Premium Access

Cardiovascular risk following cannabinoid treatment for patients with chronic pain

Congress Presentation

About the speaker

Miss Nina Nouhravesh

Duke Clinical Research Institute, Durham (United States of America)
0 follower

6 more presentations in this session

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Speaker: Doctor N. Maurea (Naples, IT)


Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials

Speaker: Associate Professor M. Schmidt (Aarhus, DK)


Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Speaker: Doctor N. Maurea (Naples, IT)


Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient

Speaker: Mr E. Fort (Barcelona, ES)


Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction

Speaker: Doctor N. Maurea (Naples, IT)


Access the full session

Drug cardiotoxicity: what do we need to know?

Speakers: Miss N. Nouhravesh, Doctor N. Maurea, Associate Professor M. Schmidt, Doctor N. Maurea, Mr E. Fort...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb